Launay-Vacher V Deray G Hypertension and proteinuria: a class-effect of antiangiogenic therapies Anticancer Drugs. 2009 20 1 81-82 
Chowdhury S Spicer J Harper P Hypertension and targeted therapy: part 1. Bevacizumab Targeted Oncology. 2006 1 2 104-108 
Chowdhury S Spicer J Harper P Hypertension and targeted therapy: part 2. Small molecule inhibitors of VEGF Targeted Oncology. 2006 1 3 172-178 
Roodhart JM Langenberg MH Witteveen E The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol. 2008 3 2 132-143 
Humphreys BD Atkins MB Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res. 2009 15 19 5947-5949 
Rixe O Billemont B Izzedine H Hypertension as a predictive factor of sunitinib activity Ann Oncol. 2007 18 6 1117 
Yang R Thomas GR Bunting S Effects of vascular endothelial growth factor on hemodynamics and cardiac performance J Cardiovasc Pharmacol. 1996 27 6 838-844 
Wei W Jin H Chen ZW Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants J Cardiovasc Pharmacol. 2004 44 5 615-621 
Steeghs N Gelderblom H Roodt JO Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor Clin Cancer Res. 2008 14 11 3470-3476 
Dechend R Luft FC Angiogenesis factors and preeclampsia Nature Med. 2008 14 11 1187-1188 
Motzer RJ Hutson TE Tomczak P Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol. 2009 27 22 3584-3590 
Sunitinib malate (SUTENT&#174;) prescribing information. Revised July 2010 
Rini BI Schiller JH Fruehauf JP Association of diastolic blood pressure (dBP) &gt;= 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). Poster presentation at the 44th annual meeting of the American Society of Clinical Oncology. Chicago, IL. May 30, 2008 to June 3, 2008. Abstract 3543
Bono P Elfving H Utriainen T Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Ann Oncol. 2009 20 2 393-394 
Dahlberg SE Sandler AB Brahmer JR Schiller JH Johnson DH Clinical course of advanced non&#8211;small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol. 2010 28 6 949-954 
Friberg G Kasza K Vokes EE Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G) J Clin Oncol. 2005 23 suppl 196s Abstract 3020
Scartozzi M Galizia E Chiorrini S Arterial hypertension correlates with clinical outcome in colorectal cancer patients with first-line bevacizumab Ann Oncol. 2009 20 2 227-230 
Gore ME Szczylik C Porta C Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol. 2009 10 8 757-763 
Motzer RJ Michaelson MD Redman BG Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol. 2006 24 1 16-24 
Motzer RJ Rini BI Bukowski RM Sunitinib in patients with metastatic renal cell carcinoma JAMA. 2006 295 21 2516-2524 
Motzer RJ Hutson TE Tomczak P Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med. 2007 356 2 115-124 
Therasse P Arbuck SG Eisenhauer EA New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst. 2000 92 3 205-216 
Chobanian AV Bakris GL Black HR Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension. 2003 42 6 1206-1252 
Motzer RJ Bacik J Murphy BA Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol. 2002 20 1 289-296 
Heng DY Xie W Regan MM Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol. 2009 27 34 5794-5799 
Zhu X Stergiopoulos K Wu S Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol. 2009 48 1 9-17 
Launay-Vacher V Ayllon J Janus N Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma [published online ahead of print November 12, 2009] Urol Oncol 
Maitland ML Bakris GL Black HR Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst. 2010 102 9 596-604 
Langenberg MH van Herpen CM De Bono J Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors J Clin Oncol. 2009 27 36 6152-6159 
Bamias A Lainakis G Manios E Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib J Chemother. 2009 21 3 347-350 
Van Heeckeren WJ Ortiz J Cooney MM Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol. 2007 25 21 2993-2995 
Hood JD Meininger CJ Ziche M VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol. 1998 274 3, pt 2 H1054-H1058 
van der Veldt AA de Boer MP Boven E Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib Anticancer Drugs. 2010 21 4 439-446 
Houk BE Bello CL Poland B Rosen LS Demetri GD Motzer RJ Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol. 2010 66 2 357-371 
